- Home
- AQST vs SLN Comparison
AQST vs SLN Comparison
Compare AQST & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- SLN
- Stock Information
- Founded
- AQST 2004
- SLN 1994
- Country
- AQST United States
- SLN United Kingdom
- Employees
- AQST N/A
- SLN N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- AQST Health Care
- SLN Health Care
- Exchange
- AQST Nasdaq
- SLN Nasdaq
- Market Cap
- AQST 272.9M
- SLN 273.9M
- IPO Year
- AQST 2018
- SLN N/A
- Fundamental
- Price
- AQST $4.07
- SLN $6.47
- Analyst Decision
- AQST Strong Buy
- SLN Buy
- Analyst Count
- AQST 7
- SLN 5
- Target Price
- AQST $11.29
- SLN $32.60
- AVG Volume (30 Days)
- AQST 1.3M
- SLN 107.6K
- Earning Date
- AQST 08-05-2025
- SLN 08-14-2025
- Dividend Yield
- AQST N/A
- SLN N/A
- EPS Growth
- AQST N/A
- SLN N/A
- EPS
- AQST N/A
- SLN N/A
- Revenue
- AQST $54,228,000.00
- SLN $27,701,000.00
- Revenue This Year
- AQST N/A
- SLN N/A
- Revenue Next Year
- AQST $45.71
- SLN N/A
- P/E Ratio
- AQST N/A
- SLN N/A
- Revenue Growth
- AQST 5.29
- SLN N/A
- 52 Week Low
- AQST $2.12
- SLN $1.97
- 52 Week High
- AQST $5.80
- SLN $22.47
- Technical
- Relative Strength Index (RSI)
- AQST 72.86
- SLN 64.49
- Support Level
- AQST $3.62
- SLN $5.33
- Resistance Level
- AQST $3.80
- SLN $6.55
- Average True Range (ATR)
- AQST 0.19
- SLN 0.44
- MACD
- AQST 0.05
- SLN 0.02
- Stochastic Oscillator
- AQST 95.43
- SLN 89.34
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.